141 related articles for article (PubMed ID: 26823566)
1. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F
Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
Hashimoto K; Kaira K; Imai H; Miura YU; Shiono A; Mouri A; Yamaguchi OU; Kobayashi K; Kagamu H; Kuji I
Anticancer Res; 2024 Apr; 44(4):1541-1551. PubMed ID: 38537960
[TBL] [Abstract][Full Text] [Related]
4. Patlak-Ki derived from ultra-high sensitivity dynamic total body [
Wang D; Qiu B; Liu Q; Xia L; Liu S; Zheng C; Liu H; Mo Y; Zhang X; Hu Y; Zheng S; Zhou Y; Fu J; Chen N; Liu F; Zhou R; Guo J; Fan W; Liu H
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3400-3413. PubMed ID: 37310427
[TBL] [Abstract][Full Text] [Related]
5. Application of an artificial intelligence-based tool in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
[TBL] [Abstract][Full Text] [Related]
6. Volume-based
Liu DN; Li CP; Li HW; Wang HY; Tian XY; Hao CY
Abdom Radiol (NY); 2024 Mar; 49(3):958-963. PubMed ID: 38245900
[TBL] [Abstract][Full Text] [Related]
7. Preoperative assessment of retroperitoneal Liposarcoma using volume-based
Liu DN; Wu JH; Li ZW; Wang HY; Tian XY; Hao CY
BMC Med Imaging; 2023 Dec; 23(1):215. PubMed ID: 38110909
[TBL] [Abstract][Full Text] [Related]
8. Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy.
Kifjak D; Hochmair M; Sobotka D; Haug AR; Ambros R; Prayer F; Heidinger BH; Roehrich S; Milos RI; Wadsak W; Fuereder T; Krenbek D; Fazekas A; Meilinger M; Mayerhoefer ME; Langs G; Herold C; Prosch H; Beer L
Eur J Radiol; 2024 Jan; 170():111198. PubMed ID: 37992608
[TBL] [Abstract][Full Text] [Related]
9. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
Cheng Y; Chen ZY; Huang JJ; Shao D
Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of
Zhang Q; Tao X; Yuan P; Zhang Z; Ying J; Guo L; Li N; Wang S; Li J; Liu Y; Guo W; Zhao S; Wu N
Cancer Med; 2023 Nov; 12(22):20864-20877. PubMed ID: 37965789
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer.
Duan C; Chaovalitwongse WA; Bai F; Hippe DS; Wang S; Thammasorn P; Pierce LA; Liu X; You J; Miyaoka RS; Vesselle HJ; Kinahan PE; Rengan R; Zeng J; Bowen SR
Phys Med Biol; 2020 Oct; 65(20):205007. PubMed ID: 33027064
[TBL] [Abstract][Full Text] [Related]
12. DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma.
Liu XS; Yuan LL; Gao Y; Ming X; Zhang YH; Zhang Y; Liu ZY; Yang Y; Pei ZJ
J Transl Med; 2023 Aug; 21(1):574. PubMed ID: 37626419
[TBL] [Abstract][Full Text] [Related]
13. Correlation between
Chen B; Tao J; Wu T; Feng H; Xie J; Zhong L; Wang S
Quant Imaging Med Surg; 2023 Dec; 13(12):7842-7853. PubMed ID: 38106249
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of
Yin X; Li J; Chen B; Liu K; Hu S
Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
[TBL] [Abstract][Full Text] [Related]
15. Promising Candidate Prognostic Biomarkers in [
Hovhannisyan-Baghdasarian N; Luporsi M; Captier N; Nioche C; Cuplov V; Woff E; Hegarat N; Livartowski A; Girard N; Buvat I; Orlhac F
J Nucl Med; 2024 Apr; 65(4):635-642. PubMed ID: 38453361
[TBL] [Abstract][Full Text] [Related]
16. Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?
Kernstine KH; Faubert B; Do QN; Rogers TJ; Hensley CT; Cai L; Torrealba J; Oliver D; Wachsmann JW; Lenkinski RE; Malloy CR; Deberardinis RJ
Ann Thorac Surg; 2020 Apr; 109(4):1019-1025. PubMed ID: 31846640
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of FDG PET-CT in differentiating lung adenocarcinoma from squamous cell carcinoma.
Maman A; Çiğdem S; Kaya İ; Demirtaş R; Ceylan O; Özmen S
EJNMMI Rep; 2024 Jan; 8(1):1. PubMed ID: 38748067
[TBL] [Abstract][Full Text] [Related]
18. Volume of interest delineation techniques for
Stevenson MG; Been LB; Hoekstra HJ; Suurmeijer AJH; Boellaard R; Brouwers AH
EJNMMI Res; 2018 Jun; 8(1):42. PubMed ID: 29881881
[TBL] [Abstract][Full Text] [Related]
19. Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients.
Weisman AJ; Kim J; Lee I; McCarten KM; Kessel S; Schwartz CL; Kelly KM; Jeraj R; Cho SY; Bradshaw TJ
EJNMMI Phys; 2020 Dec; 7(1):76. PubMed ID: 33315178
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer.
Jin L; Zhang L; Fu L; Song F; Cheng A
Ann Nucl Med; 2024 Jun; 38(6):475-482. PubMed ID: 38536655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
